Menstrual migraines can be stubborn, painful, and difficult to manage with currently available treatments.

We are inviting women aged 18–45 to join a clinical research study testing rimegepant, an approved oral medication for prevention of migraine, to see if it can help prevent menstrual migraines when taken around the start of your period.

This study will explore whether rimegepant can help reduce migraine days, improve daily functioning, and offer relief where other options may not have been effective.

By participating, you’ll play an important role in advancing migraine research while receiving close monitoring from our study team.

The study lasts about 9 menstrual cycles. During this time, every participant will receive both placebo and the study medication at different timepoints.

You may be eligible if you:

• Are 18 to 45 years of age
• Have had menstrual migraines for at least 1 year
• Have a regular menstrual cycle

What to Expect:

• The study lasts nine menstrual cycles
• Participation involves nine in-clinic visits and daily e-diary completion at home
• When completing all study visits, you may receive up to $707 in compensation plus reimbursement for travel and other study-related expenses.

Learn More:

If you’d like to see if this study is right for you, check your eligibility in the link below. 

Site Principal Investigator (Study Doctor):